Worth reading
54Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
1.7
% (year-on-year change in business revenue)Wording
Avoiding a definitive answer
How definitive the wording is.Contents of this document
Financial results presentationQ3 of the fiscal year ending December 20266 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales2,350 Millions of yen+1.7%
Operating profit-238 Millions of yen
Ordinary income-261 Millions of yen
Net income-493 Millions of yen
Full-year earnings forecast
Business revenue
2,350 Millions of yen
Operating loss
-238 Millions of yen
Ordinary loss
-261 Millions of yen
Quarterly net loss
-493 Millions of yen
EBITDA
102 Millions of yen
Progress against full-year forecast 通期の予想に対して、いまどこまで進んだかの割合です。
Business revenue
59.1 %
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Royalty income2,055 Millions of yen+20.6%
- Other income (including upfront contract fees, milestone payments and research collaboration payments)295 Millions of yen-51.4%
New initiatives
- Joint research in the metabolic and endocrine disease areas with HK inno.N
- Research on IRAK-M degradation-inducing drugs and efforts by ファイメクス to secure new alliance partners
- Start of a Phase 2 clinical trial of the sodium channel blocker licensed to Hisamitsu Pharmaceutical
Key KPIsA metric the company considers important as a management benchmark.
- Cumulative domestic prescription value for K-CAB in Korea1,854 KRW 100 million+15.3%
- Number of countries where Tegoprazan is marketed22 countries
- Market share of gastric acid secretion inhibitors in Korea15 %
- Market ranking of gastric acid secretion inhibitors in Korea1 rank
- Number of countries in which the business operates57 countries
Market Size / Share
- Global peptic ulcer drug market¥2 trillion
- U.S. peptic ulcer drug market¥4,000 100 million
- Market share of gastric acid secretion inhibitors in Korea15 %
Capital expenditures
¥3 100 million three years
Acquisition of treasury shares
To be considered flexibly in light of the financial position| Item | Details |
|---|---|
| Document type | Financial results presentation |
| Fiscal Period Covered | Q3 of the fiscal year ending December 2026 |
| Net Sales | 2,350 Millions of yen (YoY +1.7%) |
| Operating profit | -238 Millions of yen |
| Ordinary income | -261 Millions of yen |
| Net income | -493 Millions of yen |
| Full-year earnings forecast | Business revenue 2,350 Millions of yen / Operating loss -238 Millions of yen / Ordinary loss -261 Millions of yen / Quarterly net loss -493 Millions of yen / EBITDA 102 Millions of yen |
| Progress against full-year forecast | Business revenue 59.1 % |
| Breakdown of Factors Affecting the Change | Royalty income 2,055 Millions of yen (YoY +20.6%), Other income (including upfront contract fees, milestone payments and research collaboration payments) 295 Millions of yen (YoY -51.4%) |
| Key KPIs | Cumulative domestic prescription value for K-CAB in Korea 1,854 KRW 100 million (YoY +15.3%), Number of countries where Tegoprazan is marketed 22 countries, Market share of gastric acid secretion inhibitors in Korea 15 %, Market ranking of gastric acid secretion inhibitors in Korea 1 rank, Number of countries in which the business operates 57 countries |
| Acquisition of treasury shares | To be considered flexibly in light of the financial position |
| Capital expenditures | ¥3 100 million (three years) |
| Market Size / Share | Global peptic ulcer drug market ¥2 trillion, U.S. peptic ulcer drug market ¥4,000 100 million, Market share of gastric acid secretion inhibitors in Korea 15 % |
| New initiatives | Joint research in the metabolic and endocrine disease areas with HK inno.N, Research on IRAK-M degradation-inducing drugs and efforts by ファイメクス to secure new alliance partners, Start of a Phase 2 clinical trial of the sodium channel blocker licensed to Hisamitsu Pharmaceutical |
Items this document does not state (17)
Gross Profit MarginOperating profit marginSelling, general and administrative expensesResults for the three months of the current quarterSelf-assessment against the planSegment resultsUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioOrders received and order backlogKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Royalty income remained firm, while other income was below the level of the same period of the previous year. The Company states that recording other income in the fourth quarter will be necessary to achieve its full-year forecast.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.